Email Alert RSS
Volume 14 Issue 5
Sep.  2023
Turn off MathJax
Article Contents
Abstract
References
Related Articles
ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
Citation: ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
shu

Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy

  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-A-021

Beijing Municipal Commission of Sciences and Technology Z211100002921016

Dongcheng District Outstanding Talent Nurturing Program 2022-dchrcpyzz-69

More Information
  • Corresponding author:

    LI Jian, E-mail: lijian@pumch.cn

  • Received Date: May 07, 2023
  • Accepted Date: June 25, 2023
  • Available Online: July 12, 2023
  • Issue Publish Date: September 29, 2023
    Graphical Abstract
    • Abstract
  • Castleman disease (CD) is a group of rare and heterogenous hematological diseases included in the 'Rare disease catalogue' of China. Among the different clinical subtypes of CD, idiopathic multicentric Castleman disease (iMCD) is characterized by symptomatic inflammatory symptoms with poor prognosis. Interleukin-6 (IL-6) targeted therapy (eg. siltuximab) is now considered as the most important treatment option according to international and domestic treatment guidelines and consensus. On July 2022, siltuximab became available in Chinese market, heralding the era of IL-6 targeted therapy in China. Thus, it is a good time point to review the state-of-the-art technology in the field of diagnosis and treatment of CD. We also highlight some of the clinical investigations conducted by Chinese researchers.
    • FullText(HTML)
    • References (13)
  • [1]
    Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma[J]. Cancer, 1956, 9: 822-830. DOI: 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4
    [2]
    Zhang L, Dong YJ, Peng HL, et al. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria[J]. Lancet Reg Health West Pac, 2023, 34: 100720. DOI: 10.1016/j.lanwpc.2023.100720
    [3]
    van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J]. Blood, 2018, 132: 2115-2124.
    [4]
    Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease[J]. Blood, 2017, 129: 1646-1657. DOI: 10.1182/blood-2016-10-746933
    [5]
    中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42: 529-534. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWWK202107001.htm
    [6]
    Zhang MY, Jia MN, Chen J, et al. UCD with MCD-like inflammatory state: surgical excision is highly effective[J]. Blood Adv, 2021, 5: 122-128. DOI: 10.1182/bloodadvances.2020003607
    [7]
    Dong Y, Zhang L, Nong L, et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease[J]. Ann Hematol, 2018, 97: 1641-1647. DOI: 10.1007/s00277-018-3347-0
    [8]
    Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood, 2019, 133: 1720-1728. DOI: 10.1182/blood-2018-11-884577
    [9]
    Li Z, Lan X, Li C, et al. Recurrent PDGFRB mutations in unicentric Castleman disease[J]. Leukemia, 2019, 33: 1035-1038. DOI: 10.1038/s41375-018-0323-6
    [10]
    Yu L, Shi M, Cai Q, et al. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study[J]. Oncologist, 2020, 25: 963-973. DOI: 10.1634/theoncologist.2019-0986
    [11]
    Zhou J, Zhang L, Liu X, et al. Evolution of Pulmonary Involvement in Idiopathic Multicentric Castleman Disease-Not Otherwise Specified: From Nodules to Cysts or Consolidation[J]. Chest, 2023. doi: 10.1016/j.chest.2023.03.022.
    [12]
    Zhao H, Zhang M, Shen K, et al. A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in newly-diagnosed iMCD patients[J]. Blood, 2023, 141: 2654-2657.
    [13]
    Zhong NN, Liu B, Bu LL. Exploring Castleman disease in China: pre-IL-6 treatment era and advancements in knowledge[J]. Lancet Reg Health West Pac, 2023, 34: 100747. DOI: 10.1016/j.lanwpc.2023.100747
    • Related Articles

  • Related Articles

    [1]DAI Jiayuan, XU Jin, XIE Jing, SHEN Min, ZHANG Shuyang. Exploration of the Clinical Postdoctoral Teaching Model in the Department of Rare Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1224-1229. DOI: 10.12290/xhyxzz.2024-0316
    [2]LIU Qingyang, LIU Xin, WANG Shaohong, SHANG Junmei, TANG Yan, ZHANG Bo. Research of Accessibility of Rare Disease Drugs Based on the China's First List of Rare Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1208-1216. DOI: 10.12290/xhyxzz.2023-0163
    [3]ZHOU Qi, LI Qinyuan, LIU Yali, LUO Zhengxiu, ZHANG Weishe, CHEN Tong, LI Guobao, SHANG Hongcai, YANG Kehu, ZHANG Bo, CHEN Yaolong, ZHANG Shuyang. The Development of Guidelines for Rare Diseases: Past, Present and Future[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 621-628. DOI: 10.12290/xhyxzz.2022-0360
    [4]CHEN Chen, HAN Xiaohong. Clinical Trials of Rare Diseases in China over One Decade: Based on the Chinese First List of Rare Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1028-1035. DOI: 10.12290/xhyxzz.2022-0010
    [5]Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital, National Rare Diseases Committee. Expert Consensus on the Application of Multi-criteria Decision Analysis in Clinical Comprehensive Evaluation of Orphan Drugs(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 235-254. DOI: 10.12290/xhyxzz.2022-0013
    [6]YU Songlin, WANG Danchen, ZOU Yutong, MA Xiaoli, QIU Ling. The Clinical Application of Liquid Chromatography-Tandem Mass Spectrometry in the Diagnosis of Rare Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 450-455. DOI: 10.12290/xhyxzz.2021-0324
    [7]Shi CHEN, Xi BAI, Hui PAN, Hui-juan ZHU. Training of Clinical Thinking about Rare Diseases from a Case of Hypothalamic and Pituitary Mass[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 343-346. DOI: 10.3969/j.issn.1674-9081.20200057
    [8]Ren-zhi WANG, Ming FENG, Yang-hua FAN. Improve the Database of Pituitary Diseases, Carry Out High Quality Clinical Research[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 339-342. DOI: 10.3969/j.issn.1674-9081.20200040
    [9]Shuang ZHOU, Yue LI. Castleman Disease Variant of POEMS Syndrome: A Case Report[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 202-206. DOI: 10.3969/j.issn.1674-9081.20170112
    [10]Hao-peng XU, Chong ZHU, Meng-chun GONG, Shu-yang ZHANG. Research of Rare Diseases in China: from the Past to the Future[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(1): 5-9. DOI: 10.3969/j.issn.1674-9081.2018.01.002

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (300) PDF downloads (85) Cited by()
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close